Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05552976 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | PHASE3 | ACTIVE NOT_RECRUITING | 606 | — | — | Jan 10, 2023 | Jul 25, 2029 | Apr 1, 2026 | 207 | United States, Argentina +25 |
| NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | PHASE3 | RECRUITING | 810 | — | — | Sep 20, 2022 | Nov 30, 2033 | Jun 3, 2026 | 266 | United States, Argentina +27 |
| Arm | Type | Description |
|---|---|---|
| MeziKd (Mezigdomide + Carfilzomib + Dexamethasone) | EXPERIMENTAL | - |
| Kd (Carfilzomib + Dexamethasone) | ACTIVE_COMPARATOR | - |
| MeziVd (mezigdomide, bortezomib and dexamethasone) | EXPERIMENTAL | - |
| PVd (pomalidomide, bortezomib and dexamethasone) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mezigdomide | DRUG | Specified dose on specified days |
| Carfilzomib | DRUG | Specified dose on specified days |
| Dexamethasone | DRUG | Specified dose on specified days |
| Pomalidomide | DRUG | Specified dose on specified days |
| Bortezomib | DRUG | Specified dose on specified days |
Inclusion Criteria \- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:. i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or. ii) M-protein ≥ 200 milligrams (mg)/24-hour urine colle...